/
/
/

Accretion Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---56%
---42%
---224%
41%41%41%29%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
ACCPL-ST
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,902.7₹456833 Cr37.7712.0762.82₹11479 Cr
9,183₹245426 Cr83.9134.04128.41₹2568 Cr
4,859.5₹187320 Cr85.8916.7297.06₹2163 Cr
1,133.3₹113217 Cr25.099.4262.53₹5040 Cr
1,380.8₹112212 Cr33.299.7757.87₹3879 Cr
1,853.3₹101155 Cr92.526.829.25₹889 Cr
2,124.3₹97626 Cr17.6630.95154.36₹5333 Cr
2,336.1₹96859 Cr47.4213.7571.08₹1913 Cr
1,162.1₹96406 Cr29.925.3263.99₹4196 Cr
1,658.9₹93614 Cr25.2217.9596.84₹3505 Cr
202₹225 Cr23.239.79₹10 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024
₹11 Cr₹8 Cr₹4 Cr
₹44 Cr₹7 Cr₹1 Cr
₹44 Cr₹7 Cr₹1 Cr
₹55 Cr₹15 Cr₹5 Cr
₹0₹23 L₹1 Cr
₹86 L₹94 L₹6 Cr
₹27 L₹19 L₹14,000
₹1 Cr₹1 Cr₹7 Cr
₹6 Cr₹8 Cr₹7 Cr
₹3 Cr₹4 Cr₹2 Cr
₹9 Cr₹9 Cr₹4 Cr
₹4 Cr₹3 Cr₹2 Cr
₹21 Cr₹23 Cr₹15 Cr
₹77 Cr₹40 Cr₹27 Cr
₹12 Cr₹14 Cr₹13 Cr
₹15 Cr₹7 Cr₹5 Cr
₹2 Cr₹100 L₹22 L
₹13 Cr₹6 Cr₹5 Cr
₹20 L₹0₹0
₹31 L₹23 L₹0
₹0₹66,000₹13 L
₹14 Cr₹6 Cr₹5 Cr
₹28 Cr₹21 Cr₹14 Cr
₹22 Cr₹12 Cr₹6 Cr
₹4 Cr₹5 L₹9 L
₹2 L₹2 L₹6 L
₹6 Cr₹1 Cr₹2 Cr
₹60 Cr₹33 Cr₹22 Cr
₹40 Cr₹10 Cr₹7 Cr
₹3 Cr₹10 L₹0
₹77 Cr₹40 Cr₹27 Cr
₹47₹19₹14
₹47₹19₹7

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024
₹13 Cr₹10 Cr₹2 Cr
₹2 Cr₹2 Cr₹62 L
-₹26 Cr-₹10 Cr-₹15 Cr
-₹11 Cr₹2 Cr-₹12 Cr
-₹15 Cr-₹62 L-₹12 Cr
-₹9 Cr-₹2 Cr-₹5 Cr
₹27 Cr₹2 Cr₹17 Cr
₹4 Cr-₹4 L₹9 L
₹5 L₹9 L₹0
₹4 Cr₹5 L₹9 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)202.00
Volume (₹)1,200.00
High (₹)202.00
Upper Circuit212.10
Low (₹)202.00
Lower Circuit191.90
Prev Close202.00
52W High (₹)214.70
Price202.00
52W Low (₹)53.80

Share Market Cap & Key Ratios Overview

M.Cap (₹)224.54 Cr
Div. Yield (%)0.00
PE Ratio23.23
Debt to Equity0.24
Price to Book1.35
Book Value46.91
EPS (TTM)8.70
Face Value10.00
ROE (%)28.72

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
ACCPL-STNSE
LTP
1W Low
1W High
Market cap (₹)
1902.7-17.3 (-0.90%)
1900.10
1984.80
4,56,833Cr
9183-56 (-0.61%)
9087
9467
2,45,426Cr
4859.5-190.5 (-3.77%)
4857
5066
1,87,320Cr
1133.3-57.7 (-4.84%)
1125.10
1187
1,13,217Cr
1380.8-42.7 (-3.00%)
1376.70
1426.10
1,12,212Cr
1853.3-85.2 (-4.40%)
1811.70
1949
1,01,155Cr
2124.3-47.2 (-2.17%)
2118.10
2192
97,626Cr
2336.1-46.8 (-1.96%)
2335
2419.20
96,859Cr
1162.1-15.9 (-1.35%)
1154.40
1179.90
96,406Cr
1658.9+13.6 (0.83%)
1622.60
1717
93,614Cr
202+2.45 (1.23%)
198.20
210
225Cr

Accretion Pharmaceuticals Ltd Annual Results Key Takeaways

Basis: Consolidated annual results.

Accretion Pharmaceuticals Ltd Quaterly Results Key Takeaways